AllianceBernstein
STLN

AllianceBernstein’s Starling Oncology STLN Stock Holding History

AllianceBernstein’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219K Buy
71,400
+9,800
+16% +$41.2K ﹤0.01% 3113
2026
Q1 		$219K Hold
61,600
– – ﹤0.01% 3009
2025
Q4 		$219K Hold
61,600
– – ﹤0.01% 3033
2025
Q3 		$215K Buy
61,600
+23,600
+62% +$80.9K ﹤0.01% 3060
2025
Q2 		$77.9K Buy
+38,000
New +$95K ﹤0.01% 3189

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AllianceBernstein's STLN Position: Q2 2026 in Review

AllianceBernstein increased its Starling Oncology (STLN) stake by 16% in Q2 2026, buying an estimated $41.2K and bringing the position to 71,400 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #3113.

AllianceBernstein first reported a position in STLN in Q2 2025 and has held it in 5 quarters since. The position peaked at $219K in Q1 2026. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • AllianceBernstein held 71,400 shares of Starling Oncology worth $219K as of Q2 2026.
  • AllianceBernstein bought 9,800 Starling Oncology shares in Q2 2026, an estimated $41.2K.
  • Starling Oncology made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3113 holding.
  • AllianceBernstein first reported a position in Starling Oncology in Q2 2025 and has held it in 5 quarters since.
  • AllianceBernstein's Starling Oncology position peaked at $219K in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.